Home  /   Products  /   Urology  /   Tamsulosin (Omnic Ocas) controlled release 0.4 mg – [30 tablets]

Tamsulosin (Omnic Ocas) controlled release 0.4 mg – [30 tablets]

$28.98

A drug used for urinary disorders associated with benign prostatic hyperplasia. Alpha1-blocker

SKU: 62328 Category:

Description

Omnic Ocas Pharmacodynamics
Tamsulosin is a specific blocker of postsynaptic α1-adrenoreceptors located in the smooth muscle of the prostate, bladder neck and prostatic part of the urethra. Blockade of α1-adrenoreceptors by tamsulosin leads to decrease of the tone of the smooth muscles of the prostate, bladder neck and prostatic part of the urethra and improvement of the outflow of urine. Simultaneously, both symptoms of emptying and symptoms of filling caused by increased tone of smooth muscles and detrusor hyperactivity in benign prostatic hyperplasia are reduced.
The ability of tamsulosin to affect α1A subtype of adrenoreceptors is 20 times higher than its ability to interact with α1B subtype of adrenoreceptors, which are located in the vascular smooth muscle. Due to its high selectivity, tamsulosin does not cause clinically significant reduction of systemic arterial blood pressure (BP) both in patients with arterial hypertension and in patients with normal baseline BP.

Indications
Treatment of dysuric disorders in benign prostatic hyperplasia.

Contraindications
Hypersensitivity to tamsulosin or any other component of the drug.
Orthostatic hypotension (including in anamnesis).
Expressed hepatic insufficiency.
Caution:
Severe renal insufficiency (creatinine clearance less than 10 ml/min).
Pregnancy and lactation:
The drug Omnic® 0.4 mg in capsules is intended for use in males only.

Dosage and administration instructions.

  • Adults over 18 years of age and elderly patients
  • Orally, after breakfast, with water, take 1 capsule (0.4 mg) 1 time per day. It is not recommended to chew the capsule as this may affect the drug release rate.
  • In patients with impaired hepatic and renal function
  • No dosage regimen adjustment is required in patients with renal impairment and mild to moderate hepatic impairment.